Bayer to set up 27 Telemedicine Centres in 12 districts across 8 States in India
Bayer will be setting up 27 telemedicine centres in 12 districts across 8 states with implementing partners Telerad RxDx and Piramal Swasthya
Bengaluru: Bayer, a global enterprise with core competencies in the life science fields of health care and nutrition will be setting up 27 telemedicine centres in 12 districts across 8 states in India over the next two years, through Bayer Foundation India. The centres being set up in partnership with RxDx Healthcare and Piramal Swasthya, the public health arm of Piramal Foundation, are in line with the core values of Bayer to ensure timely access to quality healthcare, build local health capacities, and support local innovations.
"In line with Prime Minister's vision of digitization of health services, this telemedicine service will bring health services to the doorstep of beneficiaries and also effectively reduce the load on the health system as well as out of pocket expense for beneficiaries in the states of Bihar, Chhattisgarh, Jharkhand and UP. This telemedicine service is in line with the Piramal Swasthya's promise that it supplements and complements the government initiative of Universal Health Coverage for all. Presently Piramal Swasthya is operating over 180 telemedicine centres across three states in India." – Mr. Ishmeet Singh, Head, Tech Interventions, Piramal Foundation.
The Primary Health Care Centres (PHCs) have been identified in alignment with the District Health Officer, of this project. A trained GNM (General Nursing and Midwifery) along with the centre coordinator is responsible for the daily operations of the centre along with the General Physician (GP) who will provide necessary prescriptions. About 20 different medical specialties will be offered via teleconsultation.
Bayer plans to launch a total of 27 Telemedicine centres in 12 aspirational districts across 8 states over the next two years. Each centre is expected to cater to at least 25-35 villages, and cover between 35,000 to 50,000 beneficiaries.
Read Also - Bayer gets nod for Kerendia to treat type 2 diabetes, CKD in Japan
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.